Lilly swings to 2nd-qtr 2006 EPS of $0.76
US drug major Eli Lilly reported second-quarter 2006 earnings of $822.0 million, or $0.76 per share, versus a loss of $252.0 million, or $0.23 per share, in the like, year-ago period, when it suffered a $0.90 per share charge to settle law suits alleging a link between its top-selling antipsychotic, Zyprexa (olanzapine), and diabetes.
During the period, total sales increased 5% to $3.867 billion, driven largely by the company's newer products, particularly Cymbalta (duloxetine), a treatment for major depressive disorder and diabetic peripheral neuropathic pain, which netted the US firm $310.4 million, a 92% revenue surge on second-quarter 2005 and a 33% jump on a sequential quarter basis.
Newer products driving growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze